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    Hodgkin lymphoma (HL) is a malignancy of the lymphatic system of 
clonal B-lymphocyte origin, with a localised early or advanced form 
appearance, often accompanied by typical complaints such as weight loss, 
fever, night sweats (known as B symptoms) and itching. Its clinical profile is 
the following: it can predominantly be accompanied by an enlargement of 
supradiaphragmatic nodes and, more rarely, enlargement of infradiaphragmatic 
nodes, liver and spleen, with extranodal or bone involvement rarely affected. 
Changes in the blood cell formula (higher white blood cell count, low absolute 
lymphocyte count, eosinophilia and anaemia) and other laboratory tests 
(increased erythrocyte sedimentation, elevated LDH and ALP, reduced 
albumin levels) can be typical. Many of these factors possess prognostic value.  
 In 2017 65950 new HL patients were diagnosed worldwide and thus HL 
took the 0.5% of the overall cancer cases. The disease’s incidence is 2/100 000 
inhabitant in Hungary, which means approximately 200 newly diagnosed cases 
each year. As a result of the use of modern examination methods as well as 
risk and response adapted strategies, 80-85% of HL patients today survive or 
recover. Parallel to this, treatment-related late complications have come to the 
fore. Of these, patients’ long-term life expectancy is mostly affected by the 
development of second malignancies and appearance of organ damage (heart, 
lungs, thyroid gland). Several side effects are known to affect patients’ quality 
of life and mental health, and can thus lead to social and psychological 
disorders in patients. HL primarily affects the young adult active population, 
with a significant portion of patients at the time of diagnosis being working-
age young adults (mean age around 35 years), thus its social and economic 
importance surpasses its incidence. Long-term survivors’ social reintegration 
and return to work after treatment need to be important targets both for patient 
and society. At the Clinics of Internal Medicine of the University of Debrecen 
we examined correlations between fatigue, mental stress, anxiety and 
depression as well as quality of life in HL patients under treatment. The results 




2. Literature review      
 
2.1. Pathogenesis  
  
   Our knowledge of HL is continuously increasing but the cause of the 
disease is still not clear. It is known that cHL typical HRS cells and NLPHL 
lymphocyte predominant cells are of monoclonal, mature B cell origin. HRS 
cells mostly lose their B cell phenotypes and can display markers 
characteristics of several, other hemopoetic malignancies, as a result of which 
cHL and NLPHL, as well as cHL and all other non-Hodgkin lymphomas 
become distinguishable. 
   Both endogenous (genetic predisposition, immunological reasons) and 
exogenous factors may play a role in the pathogenesis of HL. The fact that if, 
in monozygotic twins, one member has HL, the risk of the disease in the other 
member of the twins is 100-fold higher compared to dizygotic twins suggests 
genetic susceptibility.   
 The role of several oncogenes and tumour suppressor genes in HL has 
been studied, however, no typical, reciprocal translocation was found that 
could be used in HL diagnostics. It is known that HRS cells in cHL have 
differences in their chromosomes in practically every case, of which clonal, 
numeric aberrations affecting 2p, 4p, 9p, 12p and 16p chromosomes are 
common. Constitutively activated NFκB pathway has a central role in the 
pathogenesis of HL, and the JAK/STAT pathway is only partially activated – 
all this has a key role in the development of resistance to apoptosis. 
Chromosome 9p24.1 is a recurrent genetic abnormality, which leads to 
overexpression of PD-L1, L2 ligands on HRS cell (especially in the HL-NS 
subtype, with individually changing expression). The JAK2 gene is located on 
the same chromosome; its amplification results in PD-L1 and L2 transcription. 
Increased PD-L1 expression has been detected in Epstein-Barr virus-positive 
cHL, too. In effect, as a result of the connection between PD-1 cell-surface 
receptor (on T cells) and PD-L1, apoptosis of cytotoxic T-cells in the lymph 
nodes and consequential cellular immunodeficiency occurred.         
  The three main functions of our immune system are: to protect its own 
structures, to seek out and destroy foreign bodies and to inhibit tumour growth. 
Central to these interactions are different CD4
+
 T lymphocytes (Tregulatory, 






 immunosuppressive/regulatory T 
cells play a key role. In HL they are important in creating a TH 2 
  
“background” instead of Th1 predominance (securing a proper antitumor 
background). The process of conversion is regulated by the tumour micro 
environment and the cancer cells themselves through secretion of TGF-β, IL-
10, galectin-1 and prostaglandin E2. These processes lead to 
immunosuppression by inhibiting function of CD8
+
 T-cells, dendritic and NC 
cells. In addition to this, programmed cell death ligand 1 expression (PD-L1) 
of cancer and microenvironment cells also greatly contributes to depletion of 
effector T cells, directly inhibiting cancer cell apoptosis. Involvement of the 
immune system is supported by the fact that the disease is more frequent both 
in congenital and in acquired immune deficiency conditions (human 
immunodeficiency virus (HIV), solid organ/bone marrow transplant).  
   The role of EBV infection as exogenous factor in the development of 
HL is supported by several factors. Epidemiological observations have 
revealed that the relative risk of the development of HL in patients who have 
had mononucleosis infectiosa, especially in young adulthood, is three-fold 
compared to the general population. In a considerable proportion of HL 
patients elevated EBV antibody titers can be detected years before the 
development of lymphoma. In 20-60% of cHL cases clonal EBV genome (or 
its product: latent membrane protein, LMP) can be detected in malignant HRS 
cells (in particular in MC subtype). EBV genome clonality may suggest the HL 
developed from a single infected cell.   
 
2.2 Clinical picture, diagnosis 
 
   At identification of HL most patients are complaint-free. So-called B 
symptoms General symptoms such as excruciating itchy skin can be typical 
and, rarely, pain in the affected lymph node following alcohol consumption. 
Depending on the locality of the affected lymph node region these can cause 
compression- type symptoms (oedema of the extremities, vena cava superior 
syndrome, citrus, paraplegia, etc.).  
  The typical, often only, symptom of HL is the usually painless 
enlargement of the lymph nodes. In clinically typical cases it is accompanied 
by enlarged supradiaphragmatic lymph nodes, (cervical - in 60% of cases, 
especially on the left side of the neck, and mediastinal, supraclavicular, and 
axillar - in 20% of cases). Infrequently it is accompanied by 
infradiaphragmatic lymph node involvement and enlarged liver and spleen. 
Extranodal and bone marrow involvement is not common, and the central 
  
nervous system and the gastrointestinal tract are also extremely rarely 
involved. In the case of significant adenomegalia (more than 10 cm in the 
chest and more than 5 cm on the periphery), we have a case of a „bulky” 
tumour. 
  One of the keystones of successful treatment of lymphomas, and thus of 
HL, is constituted by precise diagnosis of the disease. Even today, an 
indispensable part of the diagnosis is a classical pathomorphological 
examination completed with immunohistochemistry. Citological examination 
is not satisfactory, as it can only raise risk of the disease. Efforts need to be 
taken to perform a surgical biopsy of the affected lymph node/organ/tissue. If 
surgical sampling is not possible (old age, frail general condition, inadequate 
blood coagulation parameters, rapid progression, pregnancy, time factor), 
lymph node core biopsy can be considered as a quick, acceptable alternative 
procedure.  
      
2.3 Staging, prognostic factors, determining treatment response  
  
   Staging examinations require performance of several propedeutic, 
laboratory, and imaging examinations. Following precise history-taking 
performance of detailed physical examination is recommended (affected 
lymph node(s) region(s), size of liver and spleen). The following laboratory 
tests are performed: qualitative and quantitative blood tests, We, detailed blood 
chemistry tests (liver and kidney function tests, LDH, alkaline phosphatase, 
total protein-albumin, 2-microglobulin, serological samples (HIV, EBV, 
cytomegalovirus, hepatitis viruses), hemostasis, and, in women of fertile age, 
pregnancy tests. Furthermore, the patient’s cardiopulmonary assessment (ECG, 
echocardiography, DLCO) can also be recommended if it is possible or is 
warranted by anamnestic data. 
    Among imaging techniques used to determine extent of the disease 
PET/CT scans have a primary, standard role today. Staging PET scans can be 
important in determining extent of the disease, exploring extranodal 
localisation(s), and, in some cases, in marking biopsy sites. PET/CT has an 
indispensable role in measuring early response to therapy, done after the 
second chemotherapy (CT) cycle. This is the so-called interim PET/CT, the 
most reliable prognostic factor at present in terms of response to therapy and 
survival; the prognostic value of interim PET/CT scan performed after second-
cycle ABVD (adriablastin, bleomycin, vinblastin, dacarbazin) in advanced 
  
stage HL surpasses that of the International Prognostic Score (IPS), The 
restaging PET scan used to help in measuring response to therapy after 
treatment has a function in judging viability of residual tumour mass and 
identifying patients with an inadequate response to therapy. It can also be used 
in patient follow-up to confirm suspicion of relapse and, more rarely, to 
identify biopsy site. Using PET/CT can help us plan response-adapted 
personalised treatment, which can help us avoid over- or undertreating our 
patients. Today, evaluation of interim and restaging PET/CT examinations 
takes place in a standardised way, using the Deauville five-point scoring 
system incorporating the Deauville criteria.  
 Earlier clinical staging was done using the 1989 Cotswolds modification 
of the 1971 Ann Arbor staging system. Today the modified Ann Arbor 
classification (Lugano classification) is used. PET/CT is a standard 
examination method indispensable in HL care.  
  The observation that prognoses of patients with identical clinical stages 
may be different has resulted in the development of diverse prognostic 
systems. In HL patients, the European Organization for Research and Treating 
Cancers (EORTC) prognostic system is used in early stages of the disease, 
while in more advanced stages Hasenclever and Diehl’s IPS is applied in 
Hungary.    
    Although long-term survival of HL patients is very good, early screening 
of patients with unfavourable prognosis and precise risk estimation are not 
sufficiently effective yet. Several clinical studies have been examining the 
issue of what prognostic significance can be added to that of the traditional 
prognostic systems and interim PET/CT by the more recent biological markers 
(peripheral blood lymphocyte/monocyte ratio, TARC, tumour-associated 
macrophages, etc.) At present their exact role/function at the time of diagnosis 




    HL therapy is almost always cure-directed. First choice therapy depends 
on histology, stage, prognostic and patient-related factors. At present 80-90% 
of recently identified patients with classical HL recover due to combined 
polychemo- (CT) and radiotherapy (DT), or chemo-and radiotherapy (CMT). 
Recognition of treatment-related late complications of earlier treated patients 
has led to the realisation that early as well late side effects of treatment should 
  
not impair survival and quality of life is at least as important as the best 
possible treatment results. At present CT has come to the fore and RT has 
become secondary. 
     The current treatment of choice for HL first line treatment is ABVD. In 
early favourable stage (I-IIA) 2-4 cycles ABVD regimen and 20-30 Gy 
involved field radiotherapy (IFRT) can be recommended. In early-stage 
unfavourable disease 4-6 cycles ABVD and 30 GY are used. In the GHSG 
HD11 study each group of patients received 4 cycles of ABVD vs 4 
BEACOPP (bleomycin, etoposid, doxorubicin, cyclophosphamid, vincristin, 
procarbazin, prednison) regime followed by 20 or 30 Gy IFRT. In more 
advanced stages (III-IV), 8-cycles ABVD regime is standard. If, at the end of 
treatment, PET/CT scans remain positive (only one region) or a PET positive 
residual mass is detected after a bulky involvement/tumour mass, IFRT is 
recommended with a total of 30-36 Gy. It is an open question whether or not it 
is necessary in the case of negative PET/CT. 
  In 20-30% of patients relapse/progression occurs after the first treatment.  
In these cases, if the patient is suitable for autologous peripheral blood stem 
cell transplantation, intermediate dose CT is used as second-line treatment 
followed by autologous HSCT in case of chemosensitivity. As a result of the 
treatment, complete remission (CR) can be achieved in 50-60% of patients. 
There are several new possibilities to treat relapse/remission after autologous 
HSCT in HL such as brentuximab-vedotin, PD-1 Inhibitors, (nivolumab, 
pembrolizumab), haploidentical allogeneic HSCT, and clinical trials. To 
achieve complete or good partial remission before stem cell transplantation 
(autologous, rarely allogeneic) rituximab (R)-bendamustin chemotherapy), a 
less toxic but less effective salvage treatment was earlier used.   
   
2.5 Treatment-related late side effects  
  
   Three periods can be distinguished in the history of HL treatment: the 
first, disease-oriented period, between 1960 and 1985, where the primary 
concern was to increase HL patients’ survival rates. In the treatment-oriented 
period between 1985 and 1995 the aim was to look for an optimal treatment, 
and, in the patient-oriented period from 1995 to these days the main aim has 
become to cure patients with the fewest possible early and late side effects. 
During patient follow-up it turned out that several early and late side effects 
may arise which can be linked to the disease and, even more likely, antitumour 
  
treatments (mostly the appearance of organ damage: heart, lungs, thyroid gland 
and development of second malignancies), which may impair patients’ quality 
of life and life expectancy. 
   Several side-effects are known that impact patient’s mental health, 
potentially leading to physical, social and psychological disorders. Due to the 
use of modern treatment modalities patients with lymphoma are living longer 
hence we need to pay attention the development of mental and psychosocial 
disorders associated with the disease and its treatment.  
 
2.5.1 The concept of quality of life  
 
   Quality of life is an extremely complex, subjective, and multidimensional 
concept, which has become one of the most widely used technical terms of 
today’s medicine, health economics, and health sociology. In medicine the 
appearance of aspects of quality of life were underpinned by the definition of 
health issued by WHO in 1948. According to the resolution, health is a state of 
complete physical, mental and social well-being and not merely the absence of 
disease or infirmity. Health research deals with a part of quality of life more 
closely related to health: health-related quality of life – HRQoL. In my theses I 
use the term quality of life as a synonym for health-related quality of life.   
   As a result of modern medical treatments, a significant proportion of HL 
patients recover, thus a growing body of literature is available on long-term 
survival of patients and disease outcome. The clinical end-point of many of 
these, mostly follow-up, studies is examination of quality of life. Perceived 
extent of impairment in quality of life is not always in direct proportion to 
extent of disease/appearance of complications. This was the reason why the 
concept of Patient Reported Outcome (PRO) was introduced, in which patients 
report on their own health. The most common method of measuring quality of 






   Fatigue is a frequent, cancer-related non-specific symptom. Unlike 
tiredness experienced in everyday life, fatigue persists, and is not affected by 
rest. It is one of the most common symptoms experienced by patients with 
lymphoma accompanied by a pronounced morbidity and reduction of function. 
Fatigue can appear independently or jointly with numerous psychological and 
psychiatric diseases. The International Classification of Diseases Rev. 10 
defines cancer-related fatigue as „significant fatigue, diminished energy, or 
increased need to rest, disproportionate to any recent change in activity level 
which has been present every day during the same 2-week period in the past 
month”. In order to assess severity of fatigue objective self-completion 
questionnaires are available. The most widely used of these are Functional 
Assessment of Cancer Therapy-Fatigue (FACT-F), Functional Assessment of 
Chronic Illness Therapy (FACIT), EORTC - Quality of Life Core 30, version 3 
(EORTC QLQ-C30), and the Multidimensional Fatigue Inventory (MFI-20) 
questionnaires. The Fatigue-2 study, which analysed 379 cancer patients, 
showed that fatigue has a much greater impact on quality of life than presence 
of vomiting, depression, or pain. Fatigue has important emotional, 
psychological and financial ramifications from the aspect of both the patient 
and their environment.   
 
2.5.3 Employment status 
 
 Based on literature data the employment status of those HL patients who 
are in durable remission or have been cured varies from 71 to 85%. The 
unemployment rate in North-East Hungary was 7.2% among the 40-49-year-
old inhabitants in both gender in the analyzed timeframe/period (from 2012 to 
2015) according to the data of the Central Statistical Office (KSH), and 14.5% 
percent of the working age population was inactive. 
 
2.5.4 Mental stress, anxiety, and depression  
  
 Cancer can present numerous psychological consequences for recovered 
patients or survivors as well, which are different from the type experienced at 
onset of disease. Earlier threat of a fatal disease, and the patient’s personal 
fight with death have long-term psychological consequences, and survivors 
  
can dread the return of the disease and treatment-related late complications 
including secondary malignancies, which can lead to anxiety, depression and 
damaged body image. In the first year following establishment of diagnosis 
clinically significant anxiety or depression is likely to develop in 63% of HL 
patients, which can usually improve within a short time. After treatment, a 
proportion of patients have to face reduced interest in sex and reduced sexual 
activity. Their return to work can also be problematic primarily on account of 
negative discrimination due to psychological disorders and lasting disease, 
which, in turn, can lead to further adaptation disorders. Advanced disease and 
greater treatment toxicity may be predisposing factors to post-treatment 
adaptation problems and development of mental and psychological stress. 
Recognition of anxiety and depression is of paramount importance as they can 
be treated with psychotherapy, changes in life style and medications. There is 
scares literature on examining mental health disorder and pathological stress 
level among haematological patients, and we have not found any reference in 




3. Aims  
 
 The overall aim of our study was to examine the long-term 
improvement of HL patients’ quality of life; a realistic goal can be to 
ensure that their quality of life should not differ from that of the 
healthy/normal population: 
 
 1.  To assess incidence of fatigue and changes in quality of life among 
our regularly followed up HL patients using the EORTC QoL core 30 
version 3 questionnaires. To look for correlations between factors 
related to the patient, the disease, and treatment.  
 
 2.  To investigate our HL patients’ employment status in the context of 
disease characteristics and treatment. 
 
 3. To examine our HL patients’ incidence of psychological disorders 
(anxiety, depression, mental stress, sense of coherence, perceived 
stress, dysfunctional attitude), using a questionnaire as well as the risk 
factors contributing to their development.  
 




4. Patients and methods  
 
4.1 Assessing fatigue and quality of life                              
 
   In the first part of our study we performed assessment of fatigue and 
quality of life. 168 patients included in the study were treated between Jan 1, 
1969 and June 30, 2005. We used the validated, Hungarian-language 
questionnaire of EORTC QOL core 30 version 3 measuring instrument, the 
most widely used instrument in the international literature to assess cancer 
patients’ quality of life. It contains 30 items, the first 28 of which can be 
marked by those who fill in the questionnaire on a 4-point Likert scale while 
the last two can be scored on a 7-point Likert scale. Application for the scale is 
dependent on registration approval. After registration EORTC made the 
Hungarian-language validated version and the attached Scoring Manual 
available to us. The questionnaire contains 5 functional scales (physical, 
emotional, cognitive, and role), 3 symptom scales (fatigue, pain, nausea, and 
vomiting), one scale to assess global health and quality of life as well as 6 
simple questions (e.g. loss of appetite). Each question is closed (answers to 
questions are limited, answers can only take place within the content units 
provided by the researcher(s).  Processing and evaluation of the questionnaire 
was carried out on the basis of the EORTC Scoring Manual. First Raw Score 
(RS) was calculated, using the numerical values of the answers given to 
questions in connection with the given symptom scale (fatigue) and quality of 
life. (In regard to fatigue, we calculated the answers to 3 questions using scores 
1-4, and the 2 answers given to questions on quality of life using scores1-7). 
Fatigue Score and QL2, signalling quality of life, were also calculated and RS 
was transformed into a 0-100 scale, using linear transformation. Higher FA 
scores represented worse „results”, i.e., more severe fatigue. Based on results 
of the GHSG study, fatigue scores lower than 20 do not represent significant 
pressure ("normal level"), while scores over 40 probably represent great 
pressure ("pathological level"). Higher QL2 scores represent better quality of 
life, however, there are no precisely defined values for „normal” or 
„pathological” fatigue. International literature suggests that a 10% or greater 
change in QL2 corresponds to a „moderate change” described by patients 




4.2 Assessing employment status and mental health   
 
   In the second part of our study we selected 170 out of 201 regularly 
followed up patients with HL within the framework of cross sectional research. 
Seven of them refused to participate in the study. Between January 1, 2012 and 
March 30, we performed the examination of 163 HL patients 2015, whose 
diagnoses were established between January 1, 1969 and July 1, 2013.  
 A questioner was applied to evaluate employment state. We considered 
inactive the disabled and those who stated themselves otherwise inactive, 
while the others were recorded as active. Among life defining events we asked 
about the post-treatment loss of employment also.  
 To assess anxiety and depression the Hospital Anxiety and Depression 
Scale (HADS) questionnaire was used. The measurement instrument was 
developed by Zigmond and Snaith in 1983 to assess the mood of non-
psychiatric patients. According to Hermann et al.’s study, it can be used 
equally well in both patient and healthy populations. The questionnaire has 
since been translated into multiple languages. Validation of the Hungarian-
language was carried out by Muszbek and colleagues in 2004, on an oncology 
patient population of more than 700. Completion of the questionnaire takes 5 
to 10 minutes; it has a methodologically important feature, namely that it also 
contains reverse worded items, reducing or preventing response bias or 
agreement bias. The 14 items (7 for anxiety and 7 for depression) are scored on 
a 4-point scale (0-3), and is arrived at from a simple addition of the total 
values, with a maximum of 21 points. Based on the recommendation of 
Zigmond and Snaith, two cut-off values can be used in interpretation (8 or 
higher and 11 or higher punts). In this study we regarded the lower cut-off 
value as pathological.  
   The General Health Questionnaire (GHQ) is a self-assessment 
screening tool for the population-level assessment of mental health disorders 
including mental health issues accompanied by mood and anxiety symptoms 
and emotional distress. The term „general health questionnaire” may be 
misleading as it is suited to assess mental health only and not „general health”. 
The questionnaire reflects people’s condition in the past two weeks. In the 12-
item version each question is to be scored on a 4-point scale. Based on a 
bimodal scoring method (0-0-1-1 point) the final point is between 1 and 12. In 
patients with 5 or higher values the risk for anxiety/depression in increased.     
  
 Is order to assess sense of coherence, the Hungarian-language, validated 
version of the Sense of coherence (SOC) questionnaire was used, which is 
suitable for assessing patients’ ability to cope with stressful situations. The 
SOC represents consonance, inner harmony, and structural characteristics. 
Extent of agreement with the statements of the 13-item questionnaire can be 
scored on a 7-point Likert scale whose total score is between 13 and 91. 
Higher values are indicative of a stronger sense of coherence.  
   To assess chronic stress we used the Hungarian-language, validated 
version of the Perceived Stress Scale (PSS) a stress assessment instrument.  
The 4-item questionnaire reveals your feelings and thoughts during the last 
month. For each item, higher scores are correlated with higher numbers of 
stressful situations and more successful coping. Because of the latter, PSS 
scores are obtained by reversing responses to the four positively stated items 
and then summing across all scale items, producing the global indicator of 
perceived stress. 
    To assess dysfunctional attitude the Dysfunctional Attitude Scale form 
(DAS-A) was used. Items on the questionnaire disclose cognitive errors and 
dysfunctional thoughts that become consolidated as a result of earlier 
experience and influence an individual’s thinking about themselves and the 
world as rigid, incorrect schemes and can predict psychological problems, 
adaptation difficulties and adaptation deficit. In our study we used the 17-item 
version also validated on a Hungarian sample, which can be divided into two 
subscales (perfectionism/performance assessment vs dependence). Each item 
is to be scored on a 7-item Likert scale with the final score provided by a 
summation of the scores for the individual answers. 
 
4.3 Statistical methods  
 
Statistical analysis was performed using SPSS 15 and IBM SPSS 20 
software. Continuous variables were evaluated using independent samples t-
test, Mann-Whitney U test and, to allow comparison of more than two groups, 
variance analysis and Kruskal-Wallis test were used. To measure the 
relationship between continuous variables Spearman’s correlations were used. 
Following changes in the characteristics of HL and fatigue, and quality of life 
were measured using GLM (general linear model) repeated measures. Factors 
affecting employment characteristics of recovered patients were calculated 




5.1 Patient characteristics in the fatigue and quality of life groups  
 
   During our work we assessed frequency and severity of fatigue as well as 
quality of life in 85 female and 83 male patients with HL using the QLQ-C30 
questionnaire. Mean age of the patients at the time of questionnaire completion 
was 43.11 years (18-77 years) and the survey took place 9.5 years (0.5-36 
years) on average since diagnosis.  
 “Normal fatigue scores” (FA<20) were only found in 23.8% of patients. 
Patients with lower haemoglobin levels (females <120 g/l, males <135 g/l) at 
the time of the study showed significantly higher FA scores (FA: 44.42±27.04) 
than patients with normal haemoglobin levels (FA: 33.71±23.71; p=0.05). In 
terms of FA values we found no significant correlation between disease (sex, 
stage, B symptoms, histological subtype) and treatment (CT, RT, CMT) 
characteristics. In patients with relapsed lymphoma we found higher FA scores 
compared with patients in remission; however, the difference was not 
statistically significant. 
 Assessment of other characteristics of the treatment revealed significant 
differences between patients who had been disease-free for at least ten years 
after treatment(s), in other words, they had recovered [mean time after 
treatment(s) 16.6 years (11-33 years)] as compared to patients who had not 
been in complete remission for at least 10 years (FA: 41.36±27.60 vs. FA: 
32.86±22.68; p<0.05). Patients treated for longer than twenty years had higher 
FA (FA: 53.37±28.69) as compared to those being treated at the time (FA: 
29.35±23.04; p<0.03). Significantly higher FA values were found in patients 
who developed treatment related late complications than in patients with no 
such complications (FA: 48.72±28.29 vs. 31.88±22.20; p<0.01). We 
determined treatment-related late complications (cardiovascular, pulmonary, 
thyroid glands, secondary malignancies, changes in post-radiation skin and 
muscles, osteoporosis, ovarian dysfunction, renal damage, gastrointestinal) 
based on the results of our earlier study.  
   Quality of life score (QL2) was significantly lower in patients with late 
complications than in those without (mean QL2: 45.53±25.39 vs. mean QL2: 
67.57±21.44; p<0.001). QL2 score was also found to be significantly lower in 
recovered patients as compared to those who had not recovered (mean QL2: 
52.50±25.77 vs. QL2: 67.48±25.79; p<0.001). Mean QL2 score was lower in 
  
patients who had received only RT but the differences were not significant. No 
correlation was found between the complications determined and 
fatigue/quality of life.  
 On account of the significant differences (QL2, fatigue) between the 
group of recovered patients and that of patients with late complications we 
analysed all functional and symptom sub-scales. In patients with late 
complications the scores for physical function (PF), role function (RF), and 
emotional function (EF) were significantly lower while scores for dyspnoe 
(DY) and pain (PA) were significantly higher as compared to HL patients with 
no late complications. Physical activity had decreased and the dyspnoe score 
was higher in the group of recovered patients, in other words, patients who had 
been in remission for at least 10 years, than in the group of patients who had 
not recovered and the differences were significant. Of the 52 patients who had 
been in CR for at least 10 years, 30 had received extended field chest RT 
(mantle or total nodal RT).  
 
5.2 Patient characteristics in the employment status and mental health 
group  
 
 Relationship between employment status and quality of life was assessed 
in a total of 163 adult HL patients. Nineteen patients were pensioners (over 65) 
and employment status of four patients was not known, leading to their 
exclusion from a further subgroup analysis. We analysed data of 140 patients 
of working age (71 females, 69 males).  
 Patients’ mean age at the time of diagnosis was 32.13±13.05 years, and 
44.82±14.55 years at the time of survey completion. The most common 
histological subtype was MC (57 patients, 41%). 73 patients (53%) had early-
stage disease, 68 patients (49%) had comorbidities, with the most common of 
them being: cardiovascular: 11%, gastroenterological: 10%, dermatological: 
5%, musculoskeletal: 5%, haematological: 2%. 95 patients (67%) received 
ABVD-t, with 43 patients (31%) receiving other type of chemotherapy. 103 
patients (74%) had received irradiation therapy. Incidence of cardiovascular 
complications was significantly higher in the active than in the inactive group 
(9 vs. 12 patients, 10% vs. 25%, p=0.026), while no significant difference was 
found between the two groups in terms of other common complications 
(pulmonology disease: 7 vs 6 patients, thyroid glands: 23 vs. 17 patients, post-
radiation skin changes: 4 vs 4 patients).  
  
5.2.1 Assessing employment status  
 
 During our work we regarded employment status at the time of 
questionnaire completion as an important factor of normal life, hence we 
formed two groups: one active (93 patients) and another, inactive (47 patients).  
 The age of inactive patients at the time of diagnosis, and survey 
completion and the incidence of treatment-related late complications was 
significantly different from that of active patients. Our survivors who were still 
active were on average 10 years younger, their disease had been identified 7.5 
years earlier, the number of patients with higher educational levels was almost 
twice as high and had about half the number of complications as compared to 
the inactive group.  
 
5.2.2 Independent predictive factors of employment status 
 
  We carried out multiple regression analysis in order to identify 
determining variables and take out non-significant variables. Our results 
showed that in inactive HL patients lymphoma was identified at a later 
advanced stage (≥30 over vs below, p=0.001), their educational levels were 
lower (elementary school or higher educational level vs. college education 
p=0.032), and had more late complications (yes vs no, p<0.001) as compared 
to active patients. 
 
5.2.3 Factors accounting for treatment-related late complications  
     
  Significantly more treatment-related late complications were detected in 
female HL patients under treatment (p=0.011) and in patients who had 
received non-ABVD type treatment (p<0.001). The 71 female patients in the 
study had more relapses (p=0.003) and comorbidities (p<0.001) as compared 
to male patients (data not shown in tables). Both female sex (OR: 2.67 (95% 
CI 1.327–5.375); p=0.006) and non-ABVD type treatment (OR: 6.17 (95% CI 
2.788–13.655); p<0.001) proved to be independent predictive factors in terms 




5.2.4 Job loss as a result of HL treatment  
 
  33 patients lost their jobs due to treatment for HL, 13 of them were able 
to find employment again with 20 becoming permanently inactive. 85% 
(17/20) of the patients who had become inactive and 38% of active patients 
(5/13) had treatment-related late complications (p=0.009).  
 
5.2.5 Assessing mental health  
 
   The HADS questionnaire identified anxiety in 34 (25%), and depression 
in 14 patients (10%). Mean scores on the anxiety/depression, perceived stress, 
and stress/depression/anxiety (DAS total) as well as perfectionism subscales 
(DAS perfectionism) of the HADS instrument in inactive HL patients were 
significantly higher as compared to those in active patients. GHQ test results 
suggested pathological stress in 14 patients (10%), a score 5 times higher in 
active patients. Assessment of sense of coherence (SOC test) revealed 
significantly higher mean scores in active HL patients. With the exception of 
DAS dependence, performance of inactive patients tended to be considerably 
worse as compared to active HL patients on all questionnaires. Pathological 
scores on at least three questionnaires were regarded as signs of a severe 
mental disorder. We identified 15 patients (7 inactive, 5 active, and 3 retired 
persons) who, on the basis of their results, required immediate medical care. 
We referred 10 patients to clinical specialist consultation (clinical 
psychologist/psychiatrist), and a further 5 patients to a psychologist at this time 
already working in our clinic. Follow-up of patients showed that of the 7 





6. Discussion  
 
     Treatment of HL has become one of the success stories of 
oncohematology in recent decades. As a result of modern risk- and response-
adapted therapy today 80-85% of patients become long-term survivors and 
recover. Due to this fact, in patient care, treatment-related late complications 
have come to the fore. Of these, in our research we examined fatigue, mental 
health and the determining factors that have an impact on them.  
     Fatigue is a general, non-specific cancer symptom, which has been 
reported by literary data to be present in 50% of patients as early as time of 
diagnosis. Cancer-related fatigue is a persisting, subjective sense of physical, 
emotional or mental exhaustion, disproportionate to any recent change in 
activity level. Severe exhaustion considerably affects the everyday lives of 
both patients under treatment and those in remission. Development of fatigue 
is multifactorial, influenced by the direct effects of tumour (mass), treatment 
(CT, RT, CMT) and the side-effects thereof, comorbodities, as well as by the 
presence and development of numerous mental and psychiatric illnesses. 
Fatigue remains a real-life problem even after successful treatment of HL as its 
incidence is 2 or 3 times higher than that of the general population.  
     Our results led us to conclude that, in terms of fatigue scores, we found 
no significant correlations between the characteristics of either disease or 
response to treatment. We found higher FA scores in patients with relapses 
versus patients in complete remission, and, while quality of life was worse 
(QL2 score was lower) after single RT as first treatment, the difference was 
not statistically significant in either case. Today, it is recommended to pay 
more attention not only to effective salvage treatments but also to patients’ 
quality of life. Based on our experience, rituximab-bendamustin (completed or 
replaced with rituximab brentuximab-vedotin) therapy can be an effective and 
safe salvage therapy with a favourable side-effect profile. By using less toxic, 
alternative treatment modalities we can improve survival and quality of life of 
our refractory patients with relapses. In our studies we found significantly 
higher FA scores in patients who had lower haemoglobin levels at survey 
completion time, were suffering from treatment-related late complications and 
belonged to the group of recovered patients (disease-free for 10 years). An 
explanation for the results found in the latter group may be that, due to 
advanced age, other comorbidities also need to be taken into account during 
longer survival, and the treatments received in earlier years and decades were 
  
more toxic, hence more likely to be accompanied by treatment-related late 
complications. Examination of other characteristics of the treatment showed 
that in the group of recovered patients (disease-free for at least 10 years) FA 
scores gradually increase while QL2 scores decrease, suggesting that quality of 
life is worsening. Exceptionally bad scores can be observed in those who have 
been in remission for at least 20 years (15/52 patients), which may be related 
to the fact that 57% of these patients had received extended field chest RT 
therapy and thus had more treatment-related late complications. Our patients 
with treatment-related late complications had significantly higher FA and 
lower QL2 scores. In patients with treatment-related late complications 
physical, role and emotional functions significantly decreased while dyspnoe 
and pain scores were significantly higher as compared to HL patients with no 
treatment-related late complications. Results of our study led us to conclude 
that fatigue is one of the most common conditions accompanied by loss of 
function to which more attention should be paid during patient care. In newly-
treated patients prevention and avoidance of risk factors, if possible, are 
necessary.  
   In accordance with our findings, a Norwegian work group’s examination 
of 476 HL patients, found no significant associations between treatment type 
and persistence of fatigue. Presence of B symptoms at time of diagnosis could 
be significantly correlated with perceived fatigue; however, we found no such 
correlation in our work. Examination of 557 HL patients by another 
Norwegian work found significant associations with clinical stage group but 
not with other treatment characteristics. Results of 818 HL patients in the HSG 
study showed that fatigue was more frequent even years after treatment than in 
the control population. Level of fatigue showed associations with several 
patient- and disease-related factors (age, sex, B symptoms, occurrence of 
relapses, haemoglobin level, cancer in the family, smoking). The role of 
comorbidities in the development of disease has been confirmed by two earlier 
studies in addition to our own. Comparing their results with those of the 
„normal” population, Ng et al. concluded that, of comorbidities, it is primarily 
the occurrence of cardiovascular complications that affect occurrence of 
fatigue. 
       It is known that patients with cancer-related fatigue are usually 
underdiagnosed and not reported to health registers and a considerable 
proportion of them do not receive treatment. For efficient treatment of cancer-
related fatigue precise diagnosis and assessment are necessary, for which today 
  
we have objective measure instruments (questionnaires) at our disposal. 
Clinical treatment guidelines pay close attention to determining state of the 
disease - (remission, relapse, progression), treatment type and time and their 
fatigue-inducing effect (e.g. CT and RT are worse than surgical removal). 
Resolving potentially reversible factors such as concomitant anaemia, thyroid 
dysfunction, osteoporosis, cachexia, chronic pain, mental stress, sleep disorder 
and proper treatment of comorbidities are extremely important and often 
require multidisciplinary cooperation. An essential element of treatment is 
education of the patient’s family about cancer-related fatigue, its causes, 
importance and treatment options. According to NCCN guidelines, non-
medication treatment options are as follows: increasing physical activity, 
strengthening exercises, psychological guidance, psychosocial treatment, 
advice on eating, and sleep therapy. Majority of medication treatments can be 
suitable for treating concomitant symptoms and diseases (anaemia-
eritropoetin, cachexia-megestrol acetate). However, even today, there is not a 
single registered medicine for cancer-related fatigue. Favourable results have 
been published in connection with use of two medications. The first is 
methylphenidate, a psychostimulants, and currently available only in clinical 
trials. The second one is methylprednisolone, whose short-term use can 
contribute to improving patients’ fatigue, appetite and satisfaction.  
 Since HL primarily affects the active population, a considerable 
proportion of patients at time of diagnosis are in young adulthood (mean age 
around 35 years), thus, its social significance surpasses its incidence. 
Recovered patients’ post-treatment social reintegration and return to work are 
important objectives for the patient, the therapist and society alike. Work is an 
organising element in people’s everyday lives and a source of livelihood, one 
of the prerequisites of independent life. We planned assessment of 
employment status in our patients under treatment (recovered, in remission). 
At the time of survey completion two-thirds of our patients were in active 
employment status. Independent predictive symptoms of HL patients were 
younger age at time of diagnosis, higher qualifications, and absence of 
treatment-related late complications. No difference was found between the two 
groups in terms of patients’ sex and characteristic determined at the time of HL 
diagnosis.  
 Risk factors for late complications were female sex and non-ABVD 
chemotherapy. Through the reduction of irradiation field and doses and the 
introduction of ABVD therapy, HL treatment became more targeted, shown by 
  
a decrease in treatment-related late complications among our patients after 
2002. Treatment-related late complications, in particular, cardiovascular 
diseases clearly contribute to inactive employment status. 
   Literature data suggest that employment status of recovered HL 
patients/those in permanent remission is 71-85% while in our own patient 
population this number was 66%. Data of the Central Statistical Office (KSH) 
(https://www.ksh.hu/), unemployment rate at this time in the north-east of 
Hungary was 7.2%, (period: 2012-2015, population: 40-49 years population, 
both sexes), almost twice as high as that of our HL patients (5%). In contrast to 
this, however, the proportion of inactive HL patients was 1.5 times higher than 
in the general population (21.0% vs. 14.5%). Both our HL patients’ and the 
Central Statistical Office’s data apply to working-age populations; 
unemployed patients are registered job-seekers unlike inactive patients, who 
do not seek employment.  A quarter of our HL population live on disability 
support pension (25%). while in Sweden the corresponding number is 9%, and 
in Denmark 18% of HL patients become permanently disabled after treatment. 
These data underscore the need for more help for our long-term surviving 
patients in their return to work and rehabilitation.  
 Only five studies in the literature have examined employment status of 
HL patients’ in remission, four of which were questionnaire-based. In 1986 
Fobair et al. found that male sex, depression, age over 30 and current disease 
activity showed a close correlation with the number of hours worked. Return to 
work was not affected by disease stage or treatment type. According to data 
published in 1998 by Abrahamsen et al., 95% of 557 patients treated between 
1971 and 1991 returned to work after 18 months on average following 
treatment.  During the follow-up higher rates of unemployment were found 
among women (64% of women and 85% of men worked after 18 months 
following treatment. In 2012 Chen et al. demonstrated a correlation between 
male sex and scars in the head-and-neck region versus rejection of 
work(place). A 2015 study by Glimelius et al. showed that the risk of losing 
their job was greater in advanced-stage patients who had received full-dose 
chemotherapy, which could not be explained by development of a relapse, 
secondary malignancy or cardiovascular disease. A German work group 
examined correlations between social reintegration and treatment results in 
5360 HL patients. They found that grave FA scores (50 or greater) negatively 
influenced employment status both in women and in men (51% and 63%), 
  
whereas in the absence of grave FA scores, the corresponding numbers were 
78% and 90%, respectively. 
  During our work we used numerous validated measurement tools to 
assess the mental health of our HL patients and were able to show a close 
correlation between employment status and psychological well-being. Active 
(employed status) HL patients had significantly less anxiety, depression and 
pathological performance assessment (perfectionism) and their ability to cope 
with stressful situations was also better. In a considerable proportion of 
recovered HL patients and those in permanent remission we do not need to 
consider development of significant anxiety or depression. Results of clinical 
examinations (using HADS questionnaires) of patients with lymphoma showed 
a 15-42%, incidence for anxiety, and 4-35% for depression. In our study 
population, the HADS questionnaire showed a 25% incidence for anxiety and 
10% for depression. There is scarce literature on the use of the GHQ 
questionnaire in haematological diseases. Dutch authors studied development 
of mental stress using the GHQ questionnaire for a three-year period after 
bone-marrow transplantation. 13% of patients showed pathological/excessive 
stress, which corresponded to data of the general population. A Finnish work 
group found no correlation in terms of GHQ values between acute lymphoid 
leukaemia survivors and a control group. Use of the GHQ questionnaire 
revealed pathological stress in 10% of our HL-s, with the corresponding 
number in active patients being significantly lower. We detected pathological 
stress in 5% of active patients and over 20% in inactive patients. A Swedish 
work group examined HL patients’ sense of coherence (SOC questionnaire) 
and their mean values of their responses (66.8±11.2) were rather similar to our 
own results (66.90±11.26). No literature is available in connection with the use 
of DAS and PSS questionnaires in haematological diseases. 
   Examination of quality of life, employment status and mental health of 
HL/cancer long-term survivors, as a function of improving treatment results, is 
becoming an ever more important end-point of clinical research in this field. 
      In sum, our data have led us to conclude that employment status, 
educational level, and treatment-related late complications play key roles in 
HL patients’ quality of life. In addition to curing patients using modern 
treatment modalities, turning them into fully functioning survivors fit for work 
is also an important objective. An increasing number of clinical studies support 
the need for work rehabilitation of recovered cancer patients, including HL 
patients. In Denmark, there is an extensive tax-benefit system to provide work 
  
opportunities for patients with permanently reduced work ability. They receive 
financial compensation based on the degree of their disability as pensions. In 
Sweden, multidisciplinary interventions help promote a healthy working 
environment and healthy way of life with spiritual, psychological and 
professional support playing a role in them. In Hungary oncology patients have 
access to a social reintegration programme. At present, the Hungarian for HL 
patients does not contain guidelines in connection with work rehabilitation. 
Based on the results of our study, we recommend an extended social 
reintegration programme also for recovered HL patients in remission. With a 
view to improving our patients’ mental well-being, we have a clinical 
psychologist working at our clinic and also an Oncohematology Patients’ Club. 
It would be desirable to spend more time during follow-up sessions on the 
psychological guidance of our recovered patients in remission, potentially 





7. Novel statements 
 
1. Fatigue was detected in more than three quarters of our HL patients. FA 
scores of patients with lower haemoglobin levels were significantly higher. We 
found no correlation between disease and treatment characteristics versus 
fatigue; however, in patients with relapses FA scores were higher but not 
significantly.  
 
2.  Fatigue is more frequent among recovered patients and those with 
treatment-related late complications and their quality of life is worse, too. 
Physical, role, and emotional functions were significantly decreased in patients 
with treatment-related late complications, their dyspnoe and pain scores were 
significantly higher compared with HL patients with no treatment-related late 
complications.     
 
3.  International data for employment status of HL patients are 71-85% while 
we found this value to be 66% in our study. Unemployment rate in the 
examined period was better than that of the general population. In contrast, 
rate of inactive HL patients (due to the great number of patients on disability 
pension) was 1.5 times higher than that of the general population.  
 
4.  In our HL patients independent determining factors of employment were 
younger age at time of diagnosis, higher educational levels and absence of 
treatment-related late side effects. Risk factors for treatment-related late side 
effects were female sex and non-ABVD chemotherapy.  
 
5.  Assessment of mental health revealed a close correlation between 
employment status and mental well-being. We found significantly lower 
incidence of anxiety, depression and pathological performance assessment 






   As a result of the use of modern examination methods as well as risk and 
response adapted strategies, 80-85% of HL patients today survive or recover, 
hence treatment of HL has become one of the success stories of 
oncohaematology over the past decades. Parallel to this, treatment-related 
(late) complications have come to the fore. Of these patients’ long-term life 
expectancy is mostly affected by the development of second malignancies and 
appearance of organ damage (heart, lungs, thyroid gland). However, several 
side effects are known to affect patients’ quality of life and mental health, and 
can thus lead to social and psychological disorders in patients. HL primarily 
affects the young adult active population, with a significant portion of patients 
at the time of diagnosis being young adults (mean age around 35).Thus, its 
social and economic importance surpasses its incidence.  
   In our study we found fatigue in three-quarters of our HL patients in 
significant correlation with lower haemoglobin levels. We detected 
significantly higher fatigue scores and worse quality of life in our recovered 
patients with treatment-related late complications. One explanation for this is 
that, due to older age, other comorbidities also need to be reckoned with during 
longer survival, and treatments in earlier years and decades were more toxic, 
thus likely to lead to more late complications. Our results have led us to 
conclude that fatigue is one of the most common conditions accompanied by 
reduction in function that warrant special attention during patient care. 
    During our work we used validated measurement tools to assess HL 
patients’ mental health and demonstrated a close correlation between 
employment status and mental well-being. Our results suggest that 
independent determining factors of employment were younger age at time of 
diagnosis, higher educational level, and absence of treatment-related late 
complications. Risk factors for late complications were female sex and non-
ABVD therapy. Based on the results of our study we recommend an extensive 
social reintegration programme for recovered HL patients in remission. It is 
also desirable to dedicate more time to the psychological guidance of our 
recovered patients in remission during their follow-up care.  
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